methyl 5-[4-(ethylsulfonyl)phenoxy]-2-nitrobenzoate | 886978-05-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 5-[4-(ethylsulfonyl)phenoxy]-2-nitrobenzoate
• 英文别名: methyl 5-(4-ethylsulfonylphenoxy)-2-nitrobenzoate
• CAS: 886978-05-8
• 化学式: C₁₆H₁₅NO₇S
• 分子量: 365.364
• InChiKey: IGBWCOVQABAVTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  124
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 5-[4-(ethylsulfonyl)phenoxy]-2-nitrobenzoate 在 Raney nickel 氢气 作用下， 以 甲醇 为溶剂， 生成 methyl 2-amino-5-[4-(ethylsulfonyl)phenoxy]benzoate
  参考文献：
  名称：

  ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES

  摘要：

  公开号：

  EP1810969B1
• 作为产物：
  描述：

  2-硝基-5-氟苯甲酸甲酯 、 4-乙基磺酰苯酚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 methyl 5-[4-(ethylsulfonyl)phenoxy]-2-nitrobenzoate
  参考文献：
  名称：

  ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES

  摘要：

  公开号：

  EP1810969B1

文献信息

• Aryloxy-Substituted Benzimidazole Derivatives
  申请人：Hashimoto Noriaki

  公开号：US20080125429A1

  公开（公告）日：2008-05-29

  A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R 1 and R 2 represent a hydrogen, etc.; R 3 represents a hydrogen atom, a halogen atom, etc.; R 4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R 5 and R 6 each represent a hydrogen atom, a lower alkyl group, etc.; X 1 , X 2 , X 3 and X 4 each independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group β; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of X 1 to X 4 are carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.

  本发明提供了一种葡萄糖激酶激活剂；以及用于糖尿病的治疗和/或预防，或用于糖尿病如视网膜病变、肾病、神经病、缺血性心脏病、动脉硬化等的治疗和/或预防，以及用于肥胖症的治疗和/或预防。本发明涉及一种化合物的公式(I)：[其中R1和R2分别表示氢等；R3表示氢原子、卤原子等；R4各自独立地表示氢原子、低级烷基等；Q表示碳原子、氮原子或硫原子（硫原子可以是单取代或双取代的氧基）；R5和R6各自表示氢原子、低级烷基等；X1、X2、X3和X4各自独立地表示碳原子或氮原子；Z表示氧原子、硫原子或氮原子；Ar表示芳基或杂环芳基，可选择性地单取代至三取代于β取代基；环A表示一个含氮的5-或6成员杂芳基；m表示1至6的整数；n表示0至3的整数；p表示0至2的整数（前提是X1至X4中至少有两个是碳原子）；q表示0或1]或其药学上可接受的盐，具有葡萄糖激酶激活的作用，并且可用作糖尿病的治疗。
• Aryloxy-substituted benzimidazole derivatives
  申请人：MSD K.K.

  公开号：US07932394B2

  公开（公告）日：2011-04-26

  A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R1 and R2 represent a hydrogen, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; R4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R5 and R6 each represent a hydrogen atom, a lower alkyl group, etc.; X1, X2, X3 and X4 each independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group β; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of X1 to X4 are carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.

  本发明提供了一种葡萄糖激酶激活剂；以及一种治疗和/或预防糖尿病，或一种治疗和/或预防糖尿病如视网膜病变、肾病、神经病、缺血性心脏病、动脉硬化，以及进一步治疗和/或预防肥胖症的药物。本发明涉及公式(I)的化合物：[其中R1和R2代表氢等；R3代表氢原子、卤原子等；R4各自独立地代表氢原子、较低的烷基等；Q代表碳原子、氮原子或硫原子（硫原子可以是单取代或双取代的氧基）；R5和R6各自代表氢原子、较低的烷基等；X1、X2、X3和X4各自独立地代表碳原子或氮原子；Z代表氧原子、硫原子或氮原子；Ar代表芳基或杂环芳基，可选择性地单取代至三取代于从取代基β选择的基团；环A代表一含有5-或6-成员的含氮杂环芳基；m表示1至6的整数；n表示0至3的整数；p表示0至2的整数（但至少X1至X4中的两个为碳原子）；q表示0或1]或其药学上可接受的盐，具有葡萄糖激酶激活的作用，可用于治疗糖尿病。
• US7932394B2
  申请人：——

  公开号：US7932394B2

  公开（公告）日：2011-04-26
• ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES
  申请人：MSD K.K.

  公开号：EP1810969B1

  公开（公告）日：2013-08-07